Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Tosilate for ICU Sedation (Phase II, China)
CTR20213129Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of remimazolam in acute respiratory decompensation, sponsored by Fujian Shengdi Pharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
remimazolam
03
Conditions
acute respiratory decompensation
Beyond the preview
Go deeper on CTR20213129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213129.